[The epidemiology character of the 503 residual paralysis of acute flaccid paralysis cases]

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008 Dec;22(6):413-5.
[Article in Chinese]

Abstract

Objective: Analyze the epidemiology character of the residual paralysis(RP) of acute flaccid paralysis (AFP) in Guangdong during 1994-2007.

Methods: The viruses isolated from the excrement of RP cases were identified and typed in Guangdong from 1994 to 2007. Statistics analysis was performed to reveal the relationship among the immunization history,age,gender and the distribution of the etiology.

Results: A total of 503 RP cases were reported. 150 of which were isolated with PV and 59 were isolated with NPEV. From 1994 to 2007, The PV isolating rate ranged from 18.92% to 47.06% and was higher in winter and spring, while the NPEV isolating rate ranged from 4.17% to 25.00%. and was higher in summer and autumn. The PV isolating rate decreased as the age increased,and its isolating rate (61.11%) was highest in "0" year group. The PV isolating rate of the population of < or =2 times OPV was far higher than 3 times. The PV and NPEV isolating rate of the RP cases was higher than without RP.

Conclusion: The case with RP caused by wild poliovirus wasn't found from 1994 to 2007 in Guangdong, but the relationship of RP case was observed between < or =2 years group and < or =1 time OPV, and NPEVs probably are the potential etiological agent that cause children RP.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Acute Disease
  • Adolescent
  • Child
  • Enterovirus / classification
  • Enterovirus / isolation & purification*
  • Enterovirus Infections / epidemiology
  • Enterovirus Infections / immunology
  • Enterovirus Infections / physiopathology
  • Enterovirus Infections / prevention & control*
  • Humans
  • Immunization Programs
  • Infant
  • Infant, Newborn
  • Male
  • Paralysis / virology*
  • Paraplegia / complications*
  • Paraplegia / epidemiology*
  • Poliovirus / isolation & purification
  • Population Surveillance*
  • Risk Assessment
  • Serotyping
  • Vaccination